Results 71 to 80 of about 9,925 (218)
PLoS ONE, 2015 DYRK1A is a pleiotropic protein kinase with diverse functions in cellular regulation, including cell cycle control, neuronal differentiation, and synaptic transmission.
Katharina Rüben +5 more
doaj +1 more source
Identification of the matricellular protein Fibulin-5 as a target molecule of glucokinase-mediated calcineurin/NFAT signaling in pancreatic islets [PDF]
, 2017 Glucokinase-mediated glucose signaling induces insulin secretion, proliferation, and apoptosis in pancreatic β-cells. However, the precise molecular mechanisms underlying these processes are not clearly understood.
Kyohara Mayu +8 more
core +2 more sources
Use of anti–amyloid‐β monoclonal antibodies in persons with Down syndrome Alzheimer's disease
Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.Abstract INTRODUCTION The recent development and licensing of anti–amyloid‐β monoclonal antibodies for the treatment of early‐stage Alzheimer's disease have significantly shifted the clinical landscape. However, current use recommendations preclude the administration of these new drugs to persons who have Down syndrome.
Clíona Farrell +5 more
wiley +1 more source
Disease Models & Mechanisms, 2016 DYRK1A is important in neuronal development and function, and its excessive activity is considered a significant pathogenic factor in Down syndrome and Alzheimer's disease.
Hyeongki Kim +12 more
doaj +1 more source
Alzheimer's disease drug development pipeline: 2026
Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 2, April/June 2026.Abstract INTRODUCTION Discovery and development of new therapies for Alzheimer's disease (AD) are urgently needed to address the world's growing population of individuals on the AD pathophysiological continuum. Clinicaltrials.gov is a resource for studying drugs in development for treatment of AD. RESULTS There are currently 158 drugs in 192 AD trials.
Jeffrey L. Cummings +6 more
wiley +1 more source
[b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors [PDF]
Molecules, 2019 Since hyperactivity of the protein kinase DYRK1A is linked to several neurodegenerative disorders, DYRK1A inhibitors have been suggested as potential therapeutics for Down syndrome and Alzheimer’s disease. Most published inhibitors to date suffer from low selectivity against related kinases or from unfavorable physicochemical properties.
Christian Lechner +8 more
openaire +5 more sources
Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice
Neurobiology of Disease, 2009 Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) is a candidate gene for the Down syndrome neurological defects and may be involved in the progression of Alzheimer's disease.
Glòria Arqué +3 more
doaj +1 more source
A Thermodynamic-Based Interpretation of Protein Expression Heterogeneity in Different Glioblastoma Multiforme Tumors Identifies Tumor-Specific Unbalanced Processes [PDF]
, 2016 We describe a thermodynamic-motivated, information theoretic analysis of proteomic data collected from a series of 8 glioblastoma multiforme (GBM) tumors. GBMs are considered here as prototypes of heterogeneous cancers.
Heath, James R. +4 more
core +3 more sources
DAPK1‐Mediated Parkin Inactivation Enhances Neurotoxicity via MITOL‐Dependent Degradation
Journal of Cellular and Molecular Medicine, Volume 30, Issue 7, April 2026.ABSTRACT Parkinson's disease (PD) is characterised by progressive neurodegeneration and is marked by the formation of Lewy bodies, which are intracellular aggregates primarily composed of α‐synuclein. Mitochondrial dysfunction and impaired protein degradation pathways are thought to play critical roles in PD progression, contributing to the loss of ...
Chul Hong Park +2 more
wiley +1 more source
Treatment of Dyrk1A-dependent Mental Retardation of Down Syndrome: Isolation of Human Dyrk1A-specific shRNA [PDF]
Journal of Life Science, 2009 Down syndrome (DS) results from overexpressed genes on an extra copy of human chromosome 21. Among various phenotypes seen in DS patients, mental retardation, such as learning and memory deficits, is a major factor that prevents DS individuals from leading fully independent lives.
openaire +1 more source